Carol Stuckley MBA

Carol Stuckley, MBA is a global, strategic financial executive with proven success leading finance teams and creating shareholder value for healthcare companies.

Carol was formerly Chief Financial Officer and Senior Vice President HPS for TransUnion, Inc. Previously, Carol was a consultant at Harris & Dickey and RES Partners, and served as Chief Financial Officer, Vice President, Finance at Galderma (Nestlé Skin Health S.A.).

Carol held a nearly 23 year tenure in financial roles of increasing responsibility at Pfizer, including most recently as Assistant Treasurer, Vice President, Finance and Corporate Officer of Pfizer.

She currently sits on the Ipsen Board of Directors and serves as Chairperson of the Audit Committee.

Carol holds a Master of Arts in Economics and an MBA in International Finance from the Temple University’s Fox Business School.

Scroll to Top
pipeline chart header registrational white

SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence

Hemophilia B